IDRA - Idera Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.00
-0.80 (-9.09%)
As of 11:07AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close8.80
Open8.71
Bid8.00 x 3000
Ask8.01 x 2200
Day's Range7.71 - 8.71
52 Week Range5.20 - 22.96
Volume324,635
Avg. Volume440,898
Market Cap217.391M
Beta1.18
PE Ratio (TTM)N/A
EPS (TTM)-2.81
Earnings DateOct 26, 2017 - Oct 30, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.25
Trade prices are not sourced from all markets
  • These 3 Stocks Crushed It This Week: Are They Buys Now?
    Motley Fool2 days ago

    These 3 Stocks Crushed It This Week: Are They Buys Now?

    Can the momentum continue for these sizzling-hot stocks?

  • GlobeNewswire6 days ago

    Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet ...

  • 3 Beaten-Down Biotech Stocks: Can They Recover?
    Motley Fool8 days ago

    3 Beaten-Down Biotech Stocks: Can They Recover?

    Is there a light at the end of the tunnel?

  • ACCESSWIRE10 days ago

    Today’s Research Reports on Stocks to Watch: Portola Pharmaceuticals and Idera Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Portola Pharmaceuticals were deep in the red on Thursday after reporting second quarter results that revealed revenue and earnings miss. Idera Pharmaceuticals shares were rising after announcing that the company would be a part of a fireside chat in NYC next week. The company also reported second quarter results last week that revealed a positive earnings surprise.

  • GlobeNewswire11 days ago

    Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference

    Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that the company will participate in a fireside chat, led by Vincent Milano Idera’s Chief Executive Officer at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 10:20 a.m. Eastern Time at the Parker Hotel in New York City. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

  • BioCryst banks gross proceeds of $57.5M from offering
    American City Business Journals13 days ago

    BioCryst banks gross proceeds of $57.5M from offering

    BioCryst (Nasdaq: BCRX) has raised $57.5 million in a public offering of its common stock, according to the company, with the underwriters’ option to purchase additional shares exercised in full. BioCryst, based in Research Triangle Park, said Monday that the company has been granted Fast Track Designation by the U.S. Food and Drug Administration for its product to prevent angioedema attacks in patients with hereditary angioedema, or HAE. Proceeds of the company’s public offering will be used for further development of that product candidate – known as BCX7353 – as well as for other corporate purposes, according to BioCryst.

  • BioCryst gets FDA nod on key drug
    American City Business Journals14 days ago

    BioCryst gets FDA nod on key drug

    A key drug for BioCryst Pharmaceuticals (Nasdaq: BCRX) is now on the fast track, according to the U.S. Food and Drug Administration amid its shift to a standalone strategy. BioCryst, based in Research Triangle Park, said Monday that it has been granted Fast Track Designation by the FDA for a product designed to prevent angioedema attacks in patients with hereditary angioedema.

  • Idera Pharmaceuticals (IDRA) Reports Q2 Loss, Lags Revenue Estimates
    Zacks18 days ago

    Idera Pharmaceuticals (IDRA) Reports Q2 Loss, Lags Revenue Estimates

    Idera (IDRA) delivered earnings and revenue surprises of 26.25% and -9.44%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press18 days ago

    Idera: 2Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 59 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire18 days ago

    Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today reported its financial and operational results for the second quarter ended June 30, 2018. “The body of data that we have generated with tilsotolimod continues to demonstrate the potential positive difference this drug can make in patients who have not benefited from existing immuno-therapy.  Our mission from here is to explore the entirety of the opportunity both in melanoma and additional tumor types in order that we can offer hope to as many patients as possible,” continued Milano.

  • Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
    Motley Fool18 days ago

    Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

    Investors are cheering the orphan drug specialist's decision to raise a nice chunk of capital via a public offering.

  • GlobeNewswire24 days ago

    Idera Pharmaceuticals Announces One-for-Eight Reverse Stock Split

    Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that its Board of Directors has approved a one-for-eight reverse stock split of its common stock that will be effective at 5:00 pm Eastern Time today.  Beginning with the opening of trading on July 30, 2018, the Company’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 45168K405. As previously disclosed, at the Company’s Annual Meeting of Stockholders held on June 20, 2018, the Company’s stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a whole number ratio of not less than one-for-four and not more than one-for-eight.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...

  • GlobeNewswirelast month

    Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook

    Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, is providing an update on the company’s corporate strategy and outlook following the recent termination of its proposed merger with BioCryst Pharmaceuticals. Vincent Milano, Idera’s Chief Executive Officer stated, “Today, we advance the next chapter of our company’s future with a clear picture of our mission, which is to ultimately deliver tilsotolimod to as many patients suffering from cancer as we possibly can.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...

  • Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today
    Motley Foollast month

    Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today

    From a scuttled merger to tariff troubles, see why shares of these three companies fell hard today.

  • Why Idera Pharmaceuticals Is Sinking Today
    Motley Foollast month

    Why Idera Pharmaceuticals Is Sinking Today

    Shares plunge after its proposed merger is called off. Here's what investors need to know.

  • Spurned at the altar: BioCryst shareholders reject merger with Exton's Idera Pharmaceuticals
    American City Business Journalslast month

    Spurned at the altar: BioCryst shareholders reject merger with Exton's Idera Pharmaceuticals

    Idera shareholders voted in favor of the deal. The Chester County company will get $6M as a result of the termination.

  • Future of Idera's Cambridge office uncertain after failed merger
    American City Business Journalslast month

    Future of Idera's Cambridge office uncertain after failed merger

    The Cambridge-based immunology biotech's future is murky after a planned merger with drug developer BioCryst fell through this week.

  • Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
    Zackslast month

    Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

    Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 10) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics ...

  • No deal: BioCryst shareholders thwart merger with Idera
    American City Business Journalslast month

    No deal: BioCryst shareholders thwart merger with Idera

    There will be no deal as shareholders of Research Triangle Park-based BioCryst Pharmaceuticals have blocked the company’s proposed merger with Exton, Pennsylvania-based Idera Pharmaceuticals.

  • The Wall Street Journallast month

    [$$] Idera Pharmaceuticals and BioCryst Pharmaceuticals Terminate Merger Plans

    Inc. called off merger plans Tuesday after BioCryst shareholders voted against the proposal, triggering a $6 million penalty to be paid to Idera. Some BioCryst shareholders, including Great Point Partners LLC and RA Capital Management LLC, had publicly objected to the merger plan and noted that they intended to vote against it.

  • MarketWatchlast month

    BioCryst's stock jumps, Idera drops as proposed merger called off

    MARKET PULSE Shares of BioCryst Pharmaceuticals Inc. (bcrx) and Idera Pharmaceuticals Inc. (idra) were active in the extended session Tuesday following a brief halt after BioCryst shareholders voted down a merger between the two drug companies.

  • GlobeNewswirelast month

    Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals

    Idera Pharmaceuticals, Inc. (IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into by and among Idera and BioCryst on January 22, 2018, has been terminated.  The Merger Agreement was terminated following the July 10, 2018 special meeting of BioCryst stockholders at which BioCryst’s stockholders voted against the proposed mergers.  Separately, a majority of Idera’s stockholders voted in favor of the adoption of the Merger Agreement at a special meeting of Idera stockholders, also held on July 10, 2018.